Superworth

IN8BIO price to book ratio INAB

Market value divided by the book value of the company's net assets, since 2021.

Today, Nov 2, 2026
0.5×
5-year median
1.4×
Against its 5-year history
6th
percentile: 0 is its lowest day, 100 its highest
5-year range
0.2× to 5.7×
Peer median
1.5×

IN8BIO's price to book ratio is 0.5× as of Nov 2, 2026.

That is below its 5-year median of 1.4×, lower than on 94% of days in the last 5 years.

Over that time it ranged from 0.2× in Apr 2026 to 5.7× in May 2023.

The median for 5 healthcare stocks of a similar size is 1.5×.

Price to book ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far0.5×0.2×0.9×
20250.8×0.4×2.7×
20242.3×0.8×3.4×
20232.5×1.0×5.7×
20221.9×1.0×2.0×
20211.9×1.9×3.7×

Against its peers

Companies in Healthcare nearest IN8BIO's size, closest first, today.

CompanyPrice to book ratio
INABIN8BIO0.5×
NEPHNephros2.9×
ATNMActinium Pharmaceuticals1.5×
APTAlpha Pro Tech0.9×
SPROSpero Therapeutics1.4×
LFVNLifevantage2.2×
Peer median1.5×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on IN8BIO

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.